TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06100146

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B12 fortified flour
Description: Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unfortified cereal flour
Description: Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
Study: NCT05512481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year
Study: NCT06519292

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography (CCTA) at baseline
Description: Detailed imaging of coronary arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography (CCTA) at baseline
Description: Detailed imaging of coronary arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography (CCTA) after 1 year
Description: Detailed imaging of coronary arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography (CCTA) after 1 year
Description: Detailed imaging of coronary arteries
Study: NCT05335642

Intervention type: PROCEDURE
Intervention: EVAR
Description: Endovascular repair of abdominal aortic aneurysms

Intervention type: PROCEDURE
Intervention: EVAR
Description: Endovascular repair of abdominal aortic aneurysms
Study: NCT04850768

Intervention type: OTHER
Intervention: Saliva
Description: individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: Saliva
Description: individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: Saliva
Description: individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: gingival crevicular fluid
Description: GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: gingival crevicular fluid
Description: GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
Study: NCT06511947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation
Study: NCT04850768

Intervention type: OTHER
Intervention: gingival crevicular fluid
Description: GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
Study: NCT05081141

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test for HHV8 exposure
Description: Venipuncture for blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test for HHV8 exposure
Description: Venipuncture for blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test for HHV8 exposure
Description: Venipuncture for blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test for HHV8 exposure
Description: Venipuncture for blood sampling
Study: NCT05806281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)
Description: The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
Study: NCT06511947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation
Study: NCT05879809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The mini apps named SOUL GYM on the Wechat
Description: Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The mini apps named SOUL GYM on the Wechat
Description: Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The mini apps named SOUL GYM on the Wechat
Description: Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
Study: NCT05475977

Intervention type: DIAGNOSTIC_TEST
Intervention: MSCT chest
Description: Multi slice Computed Tomography of the chest

Intervention type: DIAGNOSTIC_TEST
Intervention: MSCT chest
Description: Multi slice Computed Tomography of the chest
Study: NCT05475977

Intervention type: DIAGNOSTIC_TEST
Intervention: MSCT chest
Description: Multi slice Computed Tomography of the chest
Study: NCT06099353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Age
Description: Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Age-HOPE-CVD App
Description: Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
Study: NCT06503627

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bladder flap dissection
Description: bladder flap dissection during caesarean section
Study: NCT05369598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative ABF followed by fitting according to clinical standard
Description: Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitting according to clinical standard followed by post-operative ABF
Description: Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
Study: NCT05247684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion
Study: NCT06099353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Age-HOPE-CVD App
Description: Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication of Genetic Risk Score
Description: General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
Study: NCT05128695

Intervention type: OTHER
Intervention: there is no intervention; the study is observational
Description: there is no intervention; the study is observational

Intervention type: OTHER
Intervention: there is no intervention; the study is observational
Description: there is no intervention; the study is observational
Study: NCT05154630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
Study: NCT04998110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory Supportive Care
Description: Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
Study: NCT05190809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goldilocks mastectomy and fat transfer
Description: Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
Study: NCT05157867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amylase trypsin inhibitors
Description: Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amylase trypsin inhibitors
Description: Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intraduodenal administration of placebo (physiological saline).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intraduodenal administration of placebo (physiological saline).
Study: NCT05899751

Intervention type: DRUG
Intervention: High-dose methotrexate
Description: High-dose methotrexate

Intervention type: DRUG
Intervention: Glucarpidase
Description: Glucarpidase
Study: NCT04655924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support System
Description: Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
Study: NCT06423534

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Health Educational Program
Description: Breastfeeding is a mother's priceless gift to her infant and nature's own method of nurturing a baby. Therefore, this study will be conducted to evaluate the primigravida mother's breastfeeding's knowledge, attitude and corrective technique through the implementation of an educational program and to ascertain the efficacy of such a program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Health Educational Program
Description: Breastfeeding is a mother's priceless gift to her infant and nature's own method of nurturing a baby. Therefore, this study will be conducted to evaluate the primigravida mother's breastfeeding's knowledge, attitude and corrective technique through the implementation of an educational program and to ascertain the efficacy of such a program.
Study: NCT04993014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circulating tumor cells
Description: Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells
Description: Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circulating tumor cells
Description: Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells
Description: Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.
Study: NCT05247684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study: NCT05626179

Intervention type: DRUG
Group type: OTHER
Intervention: [14C] IBI351
Description: The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
Study: NCT04763889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: CBT for those with an allergy and anxiety
Study: NCT04655924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System
Description: Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
Study: NCT04994665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy with omentopexy
Description: After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
Study: NCT06291467

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion.~* MINI 7.0 Mini-International Neuropsychiatric Interview :~* MADRS (Montgomery Asberg Depression Scale)~* C-SSRS (Columbia-Suicide Severity Rating Scale)~* FAST (Functioning Assessment Short Test)~Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) :~* STAI-Y (State-Trait Anxiety Inventory )~* PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain)~* SHAPS (Snaith-Hamilton-Pleasure Scale )~* CTQ (Childhood Trauma Questionnaire)~* ESUL : Echelle de solitude de l'université de Laval~* BIS-11 : (Barratt Impulsiveness Scale)~* QIDS (Quick Inventory of Depressive Symptomatology)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion.~* MINI 7.0 Mini-International Neuropsychiatric Interview :~* MADRS (Montgomery Asberg Depression Scale)~* C-SSRS (Columbia-Suicide Severity Rating Scale)~* FAST (Functioning Assessment Short Test)~Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) :~* STAI-Y (State-Trait Anxiety Inventory )~* PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain)~* SHAPS (Snaith-Hamilton-Pleasure Scale )~* CTQ (Childhood Trauma Questionnaire)~* ESUL : Echelle de solitude de l'université de Laval~* BIS-11 : (Barratt Impulsiveness Scale)~* QIDS (Quick Inventory of Depressive Symptomatology)
Study: NCT05875389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual assessment
Description: virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
Study: NCT05598853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal nivolumab and intrathecal ipilimumab
Description: Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
Study: NCT05055609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRE-515
Description: TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
Study: NCT06072846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki Energy Therapy
Description: Reiki Therapy will be applied to the intervention group
Study: NCT06340672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality Enhanced Preoperative Counseling
Description: For patients undergoing AR enhanced preoperative counseling, headset-based AR holograms of standardized patient anatomy through AnatomyX as well as patient specific anatomy through SurgicalAR will be projected to assist the surgeon in educating the patient throughout preoperative counseling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard preoperative counseling
Description: Control patients will undergo standard preoperative counseling.
Study: NCT05402722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
Study: NCT05874583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined route administration of Tranexamic acid
Description: tranexamic acid in topical route administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous route Tranexamic acid injection
Description: Intra venous route administration